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ABSTRACT 
We investigated the role of KATP channel on acute urinary retention (AUR) induced 
bladder dysfunction.  Eight-week-old female Sprague-Dawley rats were divided into 
seven groups: a sham-operated control group, an AUR group, and five AUR groups 
treated with: two different KATP channel openers namely nicorandil (3 or 10mg/kg), or 
cromakalim (100 or 300μg/kg), or one KATP channel inhibitor namely glibenclamide 
(5mg/kg).  The drugs were administered 30min before induction of AUR.  After the 
urethra was obstructed with a clip, AUR was induced by intravesical infusion of 2.5mL of 
saline via cystostomy.  Following a 30min obstruction the bladder was allowed to drain 
with a catheter in place for 60min with real-time monitoring of intravesical pressure and 
blood flow.  After the experimental period, the bladder function was assessed, using 
organ bath techniques (carbachol and 100mM KCl).  AUR increased the intravesical 
pressure and decreased the blood flow.  The subsequent catheterization decreased the 
intravesical pressure and increased the blood flow. AUR group reduced significantly the 
contractile responses to both carbachol and KCl compared with the control group. 
Nicorandil and cromakalim but not glibenclamide prevented the bladder dysfunction 
after AUR suggesting that KATP
 
 channel openers may prevent the bladder dysfunction 
caused by AUR and subsequent catheterization. 
Keywords: acute urinary retention, nicorandil, cromakalim, glibenclamide, 
pharmacological preconditioning 
 
1. Introduction 
Clinically, acute urinary retention (AUR) is often observed in patients with benign 
prostate hyperplasia (Meigs et al, 1999), diabetic autonomic neuropathy (Ewing and 
Clarke, 1982) or as a drug-related side effect (Verhamme et al, 2008).  AUR is a 
significant public health issue with significant consequences to the affected individual 
(Choong and Emberton, 2000).  Traditionally, prolonged bladder overdistension has been 
thought to simply produce stretch damage of the detrusor muscle and other bladder 
microstructures, resulting in reduced contractility of the detrusor muscle.  Several reports 
have indicated that the biochemical and metabolic status of the bladder is altered after 
prolonged overdistension (Tammela et al, 1993; Gabella et al, 1999; Saito et al, 2010). 
Previous studies from this and other laboratories have demonstrated 
that ischemia/reperfusion injury might be at least partly responsible for the prolonged 
bladder dysfunction occurring after overdistension (Lin et al, 2000; Saito and Miyagawa, 
2001).  Both in humans and animals, acute bladder overdistension induces a reduction in 
blood flow to bladder tissue resulting in partial ischemia and hypoxia; after subsequent 
catheterization, the blood supply recovers, allowing reperfusion (Lin et al, 2000; Saito 
and Miyagawa, 2001).  As with ischemia/reperfusion-injury of other organs, ischemia 
followed by subsequent reperfusion in the bladder leads to oxidative stress, inflammation, 
and neutrophil infiltration, which might contribute to the delayed recovery of the bladder 
function.  Recently, we reported that treatment with edaravone, a radical scavenger or 
sivelestat, a neutrophil elastase inhibitor are able to prevent the bladder dysfunction 
induced by rat ischemia/reperfusion
Noma (1983) originally described the ATP-sensitive potassium channel (K
 or AUR models (Kono et al, 2008; Shimizu et al, 
2009). 
ATP 
channel) in guinea pig cardiac membrane patches (Noma, 1983).  Since then, KATP 
channels have been detected in several kinds of tissues and they are localized in the 
sarcolemmal, mitochondrial and nuclear membranes (sarco KATP channels, mito KATP 
channels, and nuclear KATP channels, respectively) (Zhuo et al, 2005).  KATP channels 
play an important role in ischemia/reperfusion-injury in many tissues.  It was found that 
ischemia leads to cardiac cell apoptosis, which contributes to the injury while 
preconditioning prevents apoptosis in ischemic hearts.  Opening of KATP channels can 
protect cardiac myocytes against ischemia/reperfusion -injury, called pharmacological 
preconditioning (Zhuo et al, 2005).   There are some reports indicating that nicorandil is a 
selective mito KATP channel opener, and cromakalim is non-selective KATP channel 
opener whereas glibenclamide is a non-selective KATP
Therefore, we hypothesized that K
 channel inhibitor (Date et al, 
2005). 
ATP channel openers might prevent the bladder 
dysfunction caused by the AUR and subsequent catheterization. In the current 
international literature there is no information available regarding the effects of KATP 
channel openers or inhibitors on bladder dysfunction following AUR and subsequent 
catheterization. Thus the aim of the present study was to investigate the effects of KATP 
channel openers, nicorandil and cromakalim, and KATP channel inhibitor, glibenclamide 
in the bladder dysfunction after AUR and subsequent catheterization. 
2. Mater ials and methods 
2.1. Animals and exper imental design 
All animal experiments were conducted in accordance with the guidelines set by the 
Tottori University Committee for Animal Experimentation.  The rat experimental model 
was created as described in our previous reports (Saito and Miyagawa, 2001; Shimizu et 
al, 2009).  Eight-week-old female Sprague-Dawley rats (160-200g; SLC, Shizuoka, 
Japan) were randomly divided into seven groups (n=5-6 in each group).  Group A 
consisted of sham-operated control rats, and groups B, C, D, E, F and G undergone 30 
min of overdistension followed by 60 min of drainage; group B was non-drug treated; 
groups C and D were treated with nicorandil at a dose of 3 or 10 mg/kg body weight, 
respectively; groups E and F were treated with cromakalim at a dose of 100 or 300 μg /kg 
body weight, respectively; and group G was treated with glibenclamide 5mg/kg body 
weight. Each drug was administrated intra-abdominally 30min before inducing AUR. 
Each rat was anaesthetized with sodium pentobarbital (50mg/kg, intra-abdominally). The 
rat distal urethra was then clamped with a small clip; subsequently a cystostomy was 
made and 2.5 ml (0.5ml
 
/min) of saline was infused with an infusion pump (TOP-5200; 
TOP, Tokyo, Japan) to induce AUR. Thirty minutes after inducing urinary retention, the 
cystostomy tube was opened and the bladder was allowed to empty for another 60 min. 
The rats were euthanized with an overdose of pentobarbital (60mg/kg, 
intra-abdominally). 
2.2. Simultaneous measurements of intravesical pressure and blood flow in the 
bladder  
A cystometry catheter was connected to an external pressure transducer (P2310; 
Gould, Eastlake, OH) for the measurement of the intravesical pressure.  Simultaneously, 
the blood flow in the rat bladder was measured in vivo with a laser Doppler flow meter 
(BRL-100; Bioresearch Co., Nagoya, Japan) according to the method we described in our 
previous reports (Saito and Miyagawa, 2001; Shimizu et al, 2009).   
 
2.3. Tissue preparation and measurement of contractile force of the bladder 
Functional studies were conducted according to the methods described in our 
previous reports (Saito et al, 2008, 2010; Shimizu et al, 2009).  Briefly, longitudinal strips 
of the posterior wall of the bladder dome were mounted in organ baths (25 ml) containing 
Krebs-Henseleit solution, and bubbled with 5% CO2 and 95% O2 (37°C).  One hook was 
suspended from a transducer (type 45196 A; San-ei Instruments, Tokyo, Japan), and the 
lower hook was fixed to a plastic support leg attached to a micrometer (Mitutoyo, Tokyo, 
Japan).  Each strip was equilibrated unstretched for 30 min.  A load of 1.0 g was applied 
to each strip by micrometer adjustment, and the load was readjusted to this level 30 min 
later.  Changes in the tone of the strips were measured isometrically using force 
transducers, and the data were recorded on a personal computer (Macintosh G3; Apple 
Computer, Cupertino, CA) using the Chart v3.6.9 software and the PowerLab/16sp data 
acquisition system (AD Instruments, Castle Hill, Australia).  
 
Cumulative concentration 
response curves to carbachol were constructed, and contractile forces to 100 mM of KCl 
were also measured. 
2.4. Data analysis 
The EC50 and Emax values to carbachol were determined using a Macintosh 
computer (G3) loaded with the Chart v3.6.9 software and the Power Lab/16sp data 
acquisition system. 
 
 Contractile data were calculated as grams of active force per 
cross-sectional area in square millimeters.  The cross-sectional area was calculated by 
using the following equation: cross-sectional area = weight/ (length × 1.05), where 1.05 
is the assumed density of the smooth muscle (Saito et al, 2008; Shimizu et al, 2009).  A 
statistical comparison of differences between groups was performed with the use of 
analysis of variance and Fisher’s multiple comparison tests.  P values less than 0.05 were 
considered to be statistically significant. 
2.5. Drugs and chemicals 
Nicorandil was kindly supplied by Chugai Pharmaceutical Co. Ltd (Tokyo, Japan). 
Cromakalim and glibenclamide were purchased from Sigma-Aldrich (St. Louis, MO).  
All other chemicals are available commercially. 
3. Results 
3.1. Measurement of intravesical pressure and blood flow in the rat bladder during 
urinary retention and subsequent catheterization 
Figure 1 shows the result of the simultaneous measurement of intravesical pressure 
and blood flow in the rat bladder during urinary retention and subsequent catheterization.  
In all the experimental groups, urinary retention increased the intravesical pressure and 
decreased blood flow, and subsequent catheterization decreased intravesical pressure and 
increased blood flow.  Treatment with nicorandil or cromakalim tended to increase the 
blood flow during the catheterization phase in a dose dependent fashion, and treatment 
with glibenclamide decreased the blood flow during the catheterization phase compared 
to that in group B.  At the end of the experiments (95 minutes since induction of AUR), p 
values of  group B vs groups C, D, E, F and G in the blood flow were 0.308, 0.028, 0.812, 
0.395 and 0.180, respectively. On the other hand, there were no significant differences in 
the intravesical pressure of the bladder between any of the other groups during the 
experimental period.  These data suggest that the treatment with KATP channel openers or 
KATP channel inhibitor did not alter the intravesical pressure during AUR and subsequent 
catheterization, and that the treatment with KATP
 
 channel openers significantly increased 
the blood flow during the catheterization phase. 
3.2. Measurement of contractile response to carbachol and 100mM KCl 
The Emax and EC50
Table 1
 values for the contractile response of bladder strips to carbachol 
and the response to KCl (100 mM) were determined, and the results are shown in .  
The Emax values of carbachol in the AUR rats (group B) were markedly smaller than those 
of the control rats (group A).  Treatment with nicorandil and cromakalim KATP channel 
openers (group C-F) significantly prevented this injury.  On the other hand, treatment 
with the KATP channels inhibitor glibenclamide failed to prevent the bladder smooth 
muscle dysfunction (group G).  The EC50
 
 values of the group B were significantly greater 
than those of the control group (group A).  However, a part from the significant difference 
between groups A and B, there were no statically significant differences between any of 
the other groups (Table 1).  Contractile responses to 100 mM KCl showed a similar patter 
to that for the Emax values of carbachol in each group. 
4. Discussion 
In the present study, we clearly demonstrated that during the AUR phase the urinary 
bladder was under ischemia and that during and after drainage the bladder was under 
reperfusion.  Interestingly, although in the bladder blood flow there were no significant 
differences between any of the groups during AUR period, treatment with nicorandil or 
cromakalim increased the blood flow during the catheterization phase in a 
dose-dependent manner compared to that in the non-drug treated AUR animals.  On the 
other hand, treatment with glibenclamide decreased the blood flow during the 
catheterization phase compared to that in the non-drug treated AUR animals.  These 
phenomena may be explained by the action of the KATP channel openers. In fact, it is 
possible that the activation of the KATP channels by the KATP channel openers might have 
resulted in dilated vessels so that blood flow increased during the drainage phase.  In 
addition, as nicorandil is reported to have properties as both KATP channel opener and 
nitric oxide (NO) donor (Kamiyama et al, 2007), it is possible that NO directly dilated the 
vessels in the bladder.  Another possible mechanism could be that KATP
Gopalakrishnan and associates (1999) provided evidence for the molecular identity 
of K
 channel openers 
directly relax  the bladder smooth muscle and subsequently the blood flow increase 
during the drainage phase.      
ATP channels expressed in guinea pig bladder smooth muscle cells. Employing 
pharmacological and molecular analysis, they demonstrated that the KATP channels in the 
bladder smooth muscle cells are composed of SUR2B associated with a single inward 
rectifier, KIR 6.2. (Gopalakrishnan et al, 1999).  Fabiyi and co-workers (2003) reported 
that, KATP channel openers inhibit both neurogenic and myogenic bladder contraction 
(Fabiyi et al 2003).  Since then some investigators have reported the inhibitory effects of 
KATP channel openers on bladder contractility for the purpose of clinical use in patients 
with overactive bladder (Kamiyama et al, 2007; Yunoki et al, 2008; Akino et al, 2008).  
However, there is no information available concerning the role of KATP channels on AUR 
associated bladder dysfunction as a result of ischemia/reperfusion
The role of K
-injury. 
ATP channels in cardiovascular system has been studied adequately 
and their most prominent function is that the opening of these channels can protect 
cardiac myocytes against ischemic injury.  More specifically sarco KATP channels are 
reported to regulate the cell energy metabolism in two ways: a) one is that opening of 
sarco KATP channel accelerates phase 3 repolarization and slows down depolization, 
which will shorten action potential duration and prevent the reversal of Na+/Ca2+ 
exchanger resulting in inhibition of Ca+2 entry in the cell and b) the second way is 
induction of membrane potential hyperpolarization (Zhuo et al, 2005).  On the other hand 
in case of energy crisis, such as in an ischemia/reperfusion-injury the mitochondrial 
production of ATP is impaired by alternation of mitochondrial membrane potential, 
imbalanced trans-membrane ions transport, or over-production of free radicals.  The 
opening of mito KATP channels prevent the mitochondria from these disturbances by 
controlling the mitochondrial Ca2+ ion concentration and matrix swelling (Zhuo et al, 
2005).   
Previously we clearly demonstrated that mechanical preconditioning prevents 
ischemia/reperfusion induced bladder dysfunction in the rat (Hisadme et al, 2007).  In 
order to investigate the effect of pharmacological preconditioning on AUR-induced 
bladder dysfunction, we used three drugs namely nicorandil, cromakalim and 
glibenclamide.  Nicorandil is reported to be a selective mito KATP channel opener, and 
cromakalim is reported to be a non-selective KATP channel opener whereas glibenclamide 
is reported to be a non-selective KATP channel inhibitor (Date et al, 2005). Present 
functional studies showed that nicorandil and cromakalim but not glibenclamide 
prevented the bladder dysfunction after AUR. Our data indicate that pharmacological 
preconditioning protects the bladder smooth muscle against ischemic (and reperfusion) 
insult, and that this effect is mediated via the opening of the mito KATP channels.   
However, there are still controversies about the existence of the mito KATP channels in the 
mitochondria (Zhuo et al, 2005).  Further investigation is required to clarify the 
underlying molecular mechanisms of KATP
In conclusion, K
 channels in preventing AUR-induced bladder 
dysfunction. 
ATP
 
 channel openers prevented the bladder dysfunction caused by 
AUR and subsequent catheterization. 
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Figure legends 
Intravesical pressure and blood flow measured simultaneously dur ing exper imental 
duration.  
Nic 3: AUR rats treated with nicorandil at 3 mg/kg body weight, Nic10: AUR rats treated 
with nicorandil at 10 mg/kg body weight,  Cro 100: AUR rats treated with cromakalim at 
100μg /kg body weight, Cro 300: AUR rats treated with cromakalim at 300μg /kg body 
weight, and  Glib 5: AUR rats treated with glibenclamide 5 mg/kg body weight.  
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